XML 11 R2.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
ASSETS    
Cash and cash equivalents $ 59,295 $ 70,456
Restricted cash 335 1,396
Research and development incentives receivable 1,281 1,108
Prepaid expenses and other current assets 2,362 4,830
Total current assets 63,273 77,790
Property and equipment, net 3,038 3,523
Intangible assets, net 13,045 14,288
Right of use assets, net 1,618 1,638
Other assets 919 930
Total assets 81,893 98,169
Current liabilities:    
Accounts payable 535 350
Accrued expenses and other current liabilities 8,829 6,249
Deferred income 335 1,396
Operating lease liability - current 1,724 2,023
Total current liabilities 11,423 10,018
Non-current liabilities:    
Operating lease liability - non-current 8,571 9,258
Contingent consideration 3,063 2,871
Other non-current liabilities 1,487 1,476
Deferred tax liability, net 215 254
Total liabilities 24,759 23,877
Commitments and contingencies (Note 15)
Stockholders’ equity:    
Ordinary shares, £0.000025 nominal value; as at June 30, 2026 40,848,893 shares authorized, issued and outstanding and as at December 31, 2025 1 1
Deferred A shares, £1 nominal value; as at June 30, 2026 63,443 shares authorized, issued and outstanding and as at December 31, 2025 86 86
Additional paid-in capital 394,932 393,944
Accumulated deficit (320,208) (304,092)
Accumulated other comprehensive loss – foreign currency translation adjustments (17,738) (15,731)
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders 57,073 74,208
Noncontrolling interest 61 84
Total stockholders’ equity 57,134 74,292
Total liabilities and stockholders’ equity $ 81,893 $ 98,169